Navigation Links
Teysuno™ (S-1) Receives European Marketing Authorization as First-Line Therapy for Advanced Gastric Cancer
Date:3/14/2011

" commented Fabio M. Benedetti, MD, Chief Medical Officer of Taiho Pharma U.S.A., Inc.

Teysuno™ will be launched in Europe during the second half of 2011.

About Gastric Cancer

With an estimated 934,000 new cases per year (8.6% of all new cancer cases), gastric cancer is the fourth most common cancer worldwide, following lung, breast, and colorectal cancers. It is the second most common cause of cancer-related death, accounting for an estimated 700,000 to 800,000 deaths annually.  Nearly 70% of new cases occur in developing countries; 42% of new cases occur in China alone.

In Europe, gastric cancer is the seventh most common cancer and the sixth most common cause of cancer death, with an estimated annual mortality rate of 118,200.  In general, gastric cancer incidence rates are about twice as high among men as in women. The disease is difficult to cure unless it is diagnosed in its early stages. Unfortunately, because early gastric cancer causes few symptoms, the disease is not usually diagnosed until it has reached an advanced stage. In Europe, the five-year survival rate for gastric cancer is roughly 20% in men and 25% in women. Similarly, in the United States, the five-year survival rate for gastric cancer is 24%, though survival rates improve to 61% if the disease is detected early. However, less than one-quarter of gastric cancers are diagnosed at an early stage in the United States.  In contrast, the five-year survival rate exceeds 50% in Japan, where early gastric cancer is diagnosed relatively frequently due to mass screening efforts, which have been practiced since the 1960s.

About Teysuno

Teysuno™ was authorized for the treatment of gastric cancer in Japan in 1999. Teysuno™ is also authorized for patients with gastric cancer in South Korea, China, Singapore and Taiwan. To date, Teysuno™ has been used by more than 870,000 patients in Japan and Asia.

Ab
'/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer
2. ACT Receives Positive Opinion for Orphan Drug Designation from European Medicines Agency for hESC-Derived RPE Cells for Treatment of Stargardts Disease
3. Mylans Matrix Receives FDA Approval Under PEPFAR for Zidovudine Tablets, 100 mg
4. Everist Genomics Laboratory Receives Approval From U.S. Regulatory Authorities For High Complexity Clinical Testing
5. EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application
6. Rensselaer professor Daniel Lewis receives NSF CAREER Award
7. Pacific Shore Holdings, Inc. Receives Symbol Change Approval From FINRA
8. Boston College receives W.M. Keck Foundation funding for nanoscale optical microscope
9. CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices
10. Dr. Stefan Strauf of physics at Stevens receives NSF CAREER Award for quantum research
11. Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 Yuma Regional ... and complementary therapies brings comprehensive cancer care to ... Yuma Regional Cancer Center has officially opened. A ... program includes services such as open, semi-private and ... American Cancer Society Resource Center, hematology, rehabilitation center, ...
(Date:7/30/2014)... Md. , July 30, 2014 ... components to interrogate biology, but such devices can ... As such, researchers have looked ... in vitro metabolic engineering to characterize ... a chip. New devices are envisioned to recreate ...
(Date:7/30/2014)... , July 30, 2014  RXi Pharmaceuticals ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that ... RXI-109, for the reduction of recurrence of ... has been initiated. Logo - ...
(Date:7/30/2014)... San Diego, CA (PRWEB) July 30, 2014 ... second contract from the U.S. Environmental Protection Agency ... company’s expertise in developmental toxicity models, including tests ... on neuron formation and the formation of connections ... function. Inhibition of neurodifferentiation and synapse formation by ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3
... in Series of Global Distribution Agreements to Make ... Available to Researchers Everywhere--ZyGEM Also Announces Issuance of ... SOLANA BEACH, Calif. and HAMILTON, New Zealand ... Corp. Ltd. today announced that it has entered ...
... May 28 GenVec, Inc. (Nasdaq: GNVC ... with a single institutional investor for the sale of 9,615,385 shares ... its common stock. The shares of common stock and warrants ... stock and a warrant to purchase one share of common stock ...
... the Chinese Academy of Sciences in Beijing, scientists have ... to understand how they may help in the development ... , The research focused on rotating magnetic fields, which ... and generators. The difficulty for technology at the atomic ...
Cached Biology Technology:ZyGEM Corp. Signs Agreement to Incorporate Its Breakthrough DNA Extraction Technology Into Rubicon's Research and Diagnostic Products 2ZyGEM Corp. Signs Agreement to Incorporate Its Breakthrough DNA Extraction Technology Into Rubicon's Research and Diagnostic Products 3ZyGEM Corp. Signs Agreement to Incorporate Its Breakthrough DNA Extraction Technology Into Rubicon's Research and Diagnostic Products 4GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants 2GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants 3
(Date:7/30/2014)... baboons suggests that the route to a higher rank is ... of supportive sisters. , A female baboon,s social status is ... of her mother - the higher the mother is ranked, ... rank in female baboons is thought to be determined at ... spot in the pecking order, whereas females born to low-ranking ...
(Date:7/30/2014)... 30, 2014 NexID Biometrics , ... detection solutions for the biometric authentication industry, has ... revolutionizing online authentication with standards for strong authentication. ... "The decision to join FIDO Alliance stems from ... in use. We believe the FIDO Alliance is ...
(Date:7/30/2014)... through a massive collection of 20-million-year-old amber found in ... the effort is yielding fresh insights into ancient tropical ... collection is fully curated, a task that will take ... amber collection in the world, the researchers report. ... that of a pygmy locust, a tiny grasshopper the ...
Breaking Biology News(10 mins):Supportive moms and sisters boost female baboon's rank 2Supportive moms and sisters boost female baboon's rank 3NexID Biometrics Joins the FIDO Alliance 2Decades-old amber collection offers new views of a lost world 2
... salmon make one heck of a commute. The record holder in ... in the Clearwater River, Idaho, in April 2003. A year and ... near Japan. The most direct route between those two points ... Imagine fish that make it that far then turn around and ...
... reduces illness severity and duration in children one ... hours of symptom onset, according to new data ... Disease (WISPID) meeting in Bangkok 15-18 November. The ... incidence of respiratory tract infections, ear infections and ...
... as one-third of global energy consumption. However, unconventional changes ... emissions. ETH Zurich Professor for Sociology, Dirk Helbing, has ... could improve vehicular traffic flow by up to 95 ... ETH Zurich Chair of Sociology, a specialist in modelling ...
Cached Biology News:UW launches cutting-edge DNA 'fin-printing' project for salmon 2UW launches cutting-edge DNA 'fin-printing' project for salmon 3Tamiflu effective for treatment and prevention of influenza in children 1 year and older 2Tamiflu effective for treatment and prevention of influenza in children 1 year and older 3Traffic control systems 2Traffic control systems 3Traffic control systems 4
Taq DNA Polymerase (cloned), 250 units. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Polymerases....
Request Info...
Request Info...
Candida (IgA) -Ab EIA Sample Size: 5 l...
Biology Products: